Michael R. Page, PharmD, RPh

After promising results from early studies, investigators have received approval to start testing daratumumab in patients with multiple myeloma.

A recent trial supports noninferiority of pazopanib and sunitinib in terms of efficacy, with fewer adverse events associated with patient discomfort occurring with pazopanib than with sunitinib.

Gilotrif (afatinib) is FDA approved for treating certain non-small cell lung cancers.

Reports from the United States and Europe reference the lack of long-term effectiveness studies and the lack of comparative effectiveness studies as challenges in determining the most appropriate initial biologic disease-modifying antirheumatic drug (DMARD) treatment for patients with rheumatoid arthritis.

Sixty-eight percent of patients with preexisting liver damage and other poor prognostic factors treated with a combination of sofosbuvir and ribavirin attained functional cure of hepatitis C, as measured by sustained viral response 24 weeks after the end of treatment.

Investigators in Spain have identified a relationship between higher-complexity medication regimens and a lower likelihood of sustained viral response (SVR) after treatment for hepatitis C virus (HCV) infection.

The ATS 2013 conference focused on pulmonary care, critical care, sleep medicine, and more.

Liptruzet (ezetimibe/atorvastatin) is FDA approved for improving levels of several markers of dyslipidemia.

Diclegis (doxylamine succinate and pyridoxine hydrochloride) has been approved by the FDA for the treatment of nausea and vomiting associated with pregnancy.